6 completed, 4 unknown, 2 withdrawn, 1 terminated. 5 Phase 2, 4 Phase 1, 4 Phase 3, 2 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Unknown 3, Completed 2 |
| Phase 1 | 4 | Completed 2, Unknown 2 |
| Phase 3 | 4 | Completed 1, Terminated 1, Unknown 1, Withdrawn 1 |
| Not applicable | 2 | Completed 2 |
Follow Alzheimer Disease 5: new trials by email Literature Review of Alzheimer Disease 5 trials Research Report on Alzheimer Disease 5
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Pivotal Study of Sensory Stimulation in Alzheimer's Disease (HOPE Study) Spectris™ AD - Active, Spectris™ AD - Sham - Alzheimer Disease, Alzheimer Disease 1 | Not applicable | Completed | Cognito Therapeutics, Inc. | 673 | 2022-12-13 | 2026-09-09 |
| Evaluate the Safety and Immunogenicity of Ad5 COVID-19 Vaccines for Booster Use in Children Aged 6-17 Years. 1 Nebulized inhalation for booster groups, 2 Nebulized inhalation for booster groups, 3 Nebulized inhalation for booster groups - COVID-19 | Phase 2 | Unknown | Seventh Medical Center of PLA General Hospital | 410 | 2022-04-17 | 2023-04-13 |
| A Study to Evaluate the Safety and Immunogenicity of Ad5-nCoV and Ad5-nCoV-IH in CoronaVac Immunized Children and Adolescents Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector), Recombinant COVID-19 vaccine (adenovirus type 5 vector) for Inhalation (Ad5-nCoV-IH) - COVID-19 | Phase 3 | Terminated | CanSino Biologics Inc. | 91 | 2022-02-25 | 2023-06-15 |
| Study to Evaluate the inHaled Recombinant COVID-19 Vaccine (Adenovirus Type 5 Vector) On the Protective-Efficacy in Adults (SeiHOPE) Recombinant COVID-19 vaccine (adenovirus type 5 vector) for Inhalation (Ad5-nCoV-IH), Placebo - COVID-19 | Phase 3 | Withdrawn | CanSino Biologics Inc. | 2021-12-15 | 2023-06-18 | |
| A Clinical Trial of Immunobridging and Lot-to-lot Consistency of COVID-19 Vaccine (Ad5-nCoV) in Different Age Groups. Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) 0.5ml, Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) 0.3ml - COVID-19 | Not applicable | Completed | CanSino Biologics Inc. | 2021 | 2021-06-03 | 2023-02-08 |
| Phase I/II Clinical Trial of Recombinant Novel Coronavirus (COVID-19) Vaccine (Adenovirus Type 5 Vector) for Inhalation Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) for Inhalation, Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector), Placebo for Inhalation - COVID-19 | Phase 1 / Phase 2 | Completed | CanSino Biologics Inc. | 840 | 2021-04-21 | 2023-02-08 |
| Clinical Trial of the Immunogenicity, Safety, and Efficacy of the Gam-COVID-Vac Vaccine Against COVID-19 in Venezuela Gam-COVID-Vac, Placebo - Covid19 | Phase 3 | Unknown | Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation | 2000 | 2020-11-01 | 2020-11-24 |
| A Clinical Trial of A COVID-19 Vaccine Named Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector), Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) -placebo - COVID-19 | Phase 2 | Completed | CanSino Biologics Inc. | 480 | 2020-09-24 | 2022-10-31 |
| Phase III Trial of A COVID-19 Vaccine of Adenovirus Vector in Adults 18 Years Old and Above Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector), Placebo - COVID-19 | Phase 3 | Completed | CanSino Biologics Inc. | 44247 | 2020-09-15 | 2023-06-15 |
| Phase I/II Clinical Trial of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) in Canada Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector), Placebo - COVID-19 | Phase 1 / Phase 2 | Unknown | CanSino Biologics Inc. | 696 | 2020-08-01 | 2020-07-02 |
| Phase I Clinical Trial of a COVID-19 Vaccine in 18-60 Healthy Adults Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) - COVID-19 | Phase 1 | Completed | CanSino Biologics Inc. | 108 | 2020-03-16 | 2021-08-04 |
| A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Alzheimer's Disease No Intervention - Alzheimer Disease, Alzheimer Disease 1 | Withdrawn | ProgenaBiome | 2020-03-02 | 2025-06-05 | ||
| A Multicenter Randomized Double-blind Placebo-controlled Pilot Study of Safety, Pharmacodynamics and Efficacy of Different Treatments of Immunotherapeutic Drug Mobilan (M-VM3) in Patients With Diagnosed Prostate Cancer Mobilan (M-VM3), Placebo - Prostate Cancer | Phase 1 / Phase 2 | Unknown | Panacela Labs LLC | 24 | 2016-07-01 | 2017-09-20 |
COVID-19 (10) · Alzheimer Disease (2) · Alzheimer Disease 10 (2) · Alzheimer Disease 11 (2) · Alzheimer Disease 12 (2) · Alzheimer Disease 13 (2) · Alzheimer Disease 14 (2) · Alzheimer Disease 15 (2) · Alzheimer Disease 16 (2) · Alzheimer Disease 6 (2) · Alzheimer Disease 7 (2) · Alzheimer Disease 8 (2) · Alzheimer Disease 9 (2) · Alzheimer disease type 1 (2)
Virus Diseases (11) · Coronaviridae Infections (10) · Coronavirus Infections (10) · Infections (10) · Lung Diseases (10) · Nidovirales Infections (10) · Pneumonia (10) · Pneumonia, Viral (10) · RNA Virus Infections (10) · Respiratory Tract Diseases (10) · Respiratory Tract Infections (10) · Brain Diseases (2) · Central Nervous System Diseases (2) · Mental Disorders (2) · Neoplasms (2)
Inhalation (2) · Gam-COVID-Vac vaccine (1)
CanSino Biologics Inc. (8) · Cognito Therapeutics, Inc. (1) · Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation (1) · Panacela Labs LLC (1) · ProgenaBiome (1) · Seventh Medical Center of PLA General Hospital (1)
China (5) · Chile (2) · Russia (2) · United States (2) · Argentina (1) · Canada (1) · Mexico (1) · Pakistan (1)
Fengcai Zhu, MSD (3) · Fengcai Zhu (2) · Scott A Halperin, MD (2) · Chen Dong (1) · Guan Xuhua (1) · Joanne M Langley, MD (1) · Robbert Zusterzeel, MD, PhD, MPH (1) · Sabine Hazan, MD (1) · Stephania Passalacqua (1) · Wang Wei (1) · Zhu Fengcai (1)
PMID 32450106, PMID 34551104, PMID 34953526, PMID 37202147, PMID 37209700, PMID 37428653, PMID 37432025, PMID 38543926, PMID 39339956, PMID 41785679, PMID 41863180